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Background. Regulatory T (Treg) cell-based immunotherapies have been studied as potential cell-based modalities for promoting transplant survival. However, the efficacy of local delivery of Treg cells in corneal transplantation has not been fully elucidated. Herein, we investigated the kinetics of migration of subconjunctivally injected Treg cells and their role in promoting corneal allograft survival. Methods 
Foxp3
+ Treg cells were isolated from draining lymph nodes (DLNs) of GFP transgenic mice and were subconjunctivally injected to corneal allograft recipients. Next, Treg cells, conventional Tcells (Tconv) or a combination of both was locally injected to graft recipients, and graft survival was determined by evaluating opacity scores for 10 weeks. Transplanted mice without treatment served as controls. The frequencies of major histocompatibility complex-II +
CD11b
+ antigenpresenting cells, IFNγ +
CD4
+ Th1 cells, and CD45 + cells in the DLNs and cornea were evaluated at week 2 posttransplantation using flow cytometry. Expressions of IFNγ, IL-10 and TGF-β in the grafts were assessed using reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay. Results. GFP + Treg cells were detected in the ipsilateral cornea and DLNs of recipients 6 hours after injection. Subconjunctival injection of Treg cells significantly decreased the frequencies of mature antigen-presenting cells in the graft and DLNs, suppressed Th1 frequencies in DLNs, and inhibited CD45 + cell infiltration to the graft. Finally, locally delivered Treg cells significantly reduced the expression of IFN-γ, enhanced the levels of IL-10 and TGF-β in the graft, and promoted long-term allograft survival. Conclusions. Our study elucidates the kinetics of migration of locally delivered Treg cells and shows their role in suppressing host immune response against the allograft. C orneal transplantation is the most commonly performed form of solid tissue transplantation worldwide, with nearly 40000 cases of penetrating keratoplasty performed annually in the U.S. alone. 1, 2 Despite the remarkably high success rates of corneal grafts, largely due to the immune privileged status of the cornea, immune-mediated rejection still remains the major cause of corneal graft failure. 3 In addition, currently available immunosuppressive drugs are associated with several adverse side effects. It is, therefore, imperative to develop safer and more effective immunomodulatory strategies to improve corneal allograft survival.
Regulatory T (Treg) cells play a critical role in immune homeostasis and induction of tolerance toward self-and alloantigens. 4 As a promising strategy, Treg cell-based immunotherapies have been investigated in treatment of autoimmune diseases, such as multiple sclerosis 5 and uveitis 6 as well as in promoting survival of grafts in several organs, including skin, 7 islet, 8 heart, 9 and liver. 10 These therapies have mostly relied on either in vitro polyclonal expansion of Treg cells followed by their adoptive transfer to graft recipients prior to transplantation, or using molecular therapies to reconstitute Treg cells while suppressing pathogenic effector T cells. 11, 12 The relevance of Treg cells in induction of tolerance against corneal allografts has been well established. The functional status of Treg cells, primarily their expression of Foxp3, has been correlated with their ability to promote corneal graft survival. 13 Our group has previously shown that intravenous injection of allograft acceptor-derived Treg cells or ex vivo-conditioned CCR7
high Treg cells significantly reduces corneal allograft rejection rates. 13, 14 Reports from other groups have also demonstrated that adoptive transfer of in vitro expanded Treg cells to allograft recipients promotes corneal graft survival. 15 Despite the promising results of these studies, however, a major obstacle in translating adoptive transfer approaches into clinical treatments is the relatively low frequencies of Treg cells, which necessitates in vitro expansion of Treg cells before adoptive transfer in order to yield sufficient number of cells to reach the cornea and effectively target alloreactive effector cells. 16 Prolonged in vitro expansion of Treg cells itself can accentuate loss of Foxp3 expression by Treg cells and thus decrease their suppressive function. 17 A therapeutic alternative to overcome these limitations would consist of local delivery of Treg cells to graft recipients via subconjunctival injection. However, little is known about the effect of local delivery of Treg cells in regulating the alloimmune response toward the graft, and the dynamics of distribution of Treg cells upon subconjunctival injection have not yet been fully elucidated.
Herein we show for the first time that locally administered Treg cells specifically migrate from the conjunctiva to the ipsilateral cornea and draining lymph nodes (DLNs) of graft recipients, where they promote allograft survival by suppressing antigen-presenting cell (APC) maturation, Th1 cell activation, and inflammatory cell infiltration at the ocular surface. 
MATERIALS AND METHODS

Orthotopic Corneal Transplantation
Corneal transplantation was performed using C57BL/6 mice as donors and BALB/c mice as graft recipients, as described previously. 18 Briefly, the central cornea of donor C57BL/6 mice was marked with a 2 mm diameter trephine and excised with Vannas scissors (Storz Instruments Company, San Damis, CA). Recipient graft beds were prepared by excising a 1.5 mm diameter area in the central cornea of BALB/c mice. Donor buttons were transplanted and secured into host beds with 8 interrupted 11-0 nylon sutures. Eyelids were closed for 24 hours with 8-0 nylon sutures. Corneal sutures were removed at day 7 after transplantation.
Evaluation of Graft Survival
Transplanted corneas were examined weekly in a masked fashion for 10 weeks using a slit-lamp microscope. A standardized opacity grading system was used to define rejection. 19 Grafts with opacity scores higher than 2 for at least 2 consecutive weeks were considered as immune-rejected. 20 Eyes with complications, such as hemorrhage, cataract, or infection, were excluded from the analysis. − Tconv or combination of both were suspended in 10-μL phosphate buffered saline and injected subconjunctivally to mice using a 33-gauge metal needle and 100-μL syringe (Hamilton Company, Reno, NV) immediately after corneal transplantation. Transplanted mice without receiving a subconjunctival injection served as the control.
Cornea and Conjunctiva Digestion and Lymph Node Cell Preparation
Excised corneas and conjunctiva were digested in RPMI media (Lonza, Walkersville, MD) containing 2 mg/mL DNase I (Roche, Mannheim, Germany) and 4 mg/mL Collagenase D (Roche, Mannheim, Germany) for 60 minutes in 37°C and filtered through a 70-μm cell strainer. Ipsilateral draining submandibular and cervical lymph nodes were collected after transplantation and single cell suspensions were prepared. Spleen single cell suspensions were made and red blood cell lysis was performed using red blood cell lysis buffer (SigmaAldrich, St. Louis, MO).
Flow Cytometry
All cell suspensions were incubated with an Fc receptor blocking antibody (R&D Systems, Minneapolis, MN) for 10 minutes to avoid nonspecific staining, and were subsequently stained with the following antibodies: anti-CD11b (M1/70), antimouse I-A/I-E (major histocompatibility complex [MHC] II, M5/114.15.2), anti-CD4 (RM4-5) and anti-IFNγ (XMG1.2) (Biolegend, San Diego, CA). For intracellular IFNγ staining, cells were stimulated with phorbol 12-myristate 13-acetate (50 ng/mL; Sigma-Aldrich) and Ionomycin (500 ng/mL; Sigma-Aldrich) overnight in the presence of Golgistop (0.7 μL/100 μL media; BD Biosciences, San Jose, CA), and were fixed and permeabilized with appropriate buffers (eBioscience). Proper isotype controls were used for all antibodies. Stained cells were analyzed using the LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ), and the results were analyzed using FlowJo software (FlowJo LLC, Ashland, OR).
Enzyme-linked Immunosorbent Assay
Corneas were collected in PBS, homogenized on ice and centrifuged. The supernatant was assayed using commercial ELISA kits for total protein (Pierce BCA Protein Assay Kit; Thermo scientific, IL), IL-10, TGF-β1, and IFNγ (eBioscience) according to the manufacturers' instructions.
Real Time-PCR
Corneas were collected in Trizol (Ambion, Life Technologies, Grand Island, NY), and then homogenized on ice. Briefly, the RNA was extracted and purified by using RNeasy Micro kit (Qiagen, Valencia, CA). Total RNA was reverse transcripted using a Superscript III kit (Invitrogen, Carlsbad, CA). Real-time PCR was performed using TaqMan Universal PCR Mastermix (Applied Biosystems, Foster City, CA) and preformulated primers for IFNγ (Mm01168134_m1), and GAPDH (Mm99999915_gl). The results were analyzed using the CalQplex threshold and normalized using GAPDH as an internal control.
Statistical Analysis
The Kaplan-Meier survival curve was used to determine graft survival and the log-rank test was used to compare survival rates between the groups. Student's t test or Mann-Whitney U test were used for comparison of quantitative data between each 2 groups, when appropriate. In case of zero value in 1 group, 1-sample t test was used for such comparison. Results are presented as mean ± SEM. P < 0.05 was considered statistically significant.
RESULTS
Treg Cells Migrate to the Ipsilateral Cornea and DLNs of Graft Recipients After Subconjunctival Injection
In order to determine the kinetics of Treg cell migration after subconjunctival injection, 1 Â 10 5 GFP + Treg cells were injected into graft recipients immediately after performing allogeneic corneal transplantation. Ipsilateral conjunctiva, cornea, and cervical and submandibular DLN were harvested at 6 hours, 48 hours, and 7 days posttransplantation, and the absolute and percentage frequencies of GFP
+ Treg cells were determined using flow cytometry. In the ipsilateral conjunctiva, Treg cells were predominantly detected 6 hours after injection and decreased gradually in number by day 7 (Figure 1) . In ipsilateral corneas, Treg cells could be detected in low frequencies at 6 hours postinjection, but reached their maximum frequencies after 48 hours. In ipsilateral DLNs, Treg cells were observed 6 hours after injection, slightly increased in number after 48 hours, and were nearly undetectable on day 7 postinjection (Figure 1 ).
Subconjunctivally Injected Treg Cells Suppress Corneal and Lymphoid APC Maturation
During inflammation, corneal APCs undergo maturation and express high levels of MHC class II and costimulatory molecules. 21, 22 These cells play a fundamental role in mediating the adaptive immune responses, as they migrate to DLNs via afferent lymphatics and present alloantigens to naïve T cells. 23, 24 We thus investigated whether subconjunctivally injected Treg cells can inhibit the maturation of APCs in the cornea and DLNs. 1 Â 10 5 Treg cells, Tconv or combination of both was delivered via subconjunctival injection to mice immediately after allogeneic corneal transplantation. Transplanted mice not receiving subconjunctival treatment served as controls. The ipsilateral corneas and DLNs were harvested on day 14 after surgery. Previous work from our group has showed day 14 to be the optimal time point for evaluation of the immune response to allograft prior to the onset of graft rejection at week 3. In ipsilateral conjunctiva, Treg cells were predominantly detected at 6 hours, and decreased gradually from 6 hours to day 7. In ipsilateral corneas, Treg cells were detected at 6 hours postinjection, but reached their maximum frequencies after 48 hours. In ipsilateral DLN, Treg cells were detected at 6 hours, slightly increased in frequencies at 48 hours, and were undetectable on day 7. Ipsi, ipsilateral; Conj, conjunctiva; preinj., preinjection; postinj., postinjection. Data represents mean ± SEM of 2 independent experiments and each time point consists of 4 mice.
Treg cells alone, and not with combination of Treg cells and conventional T cells, compared with Tconv-treated (P = 0.024) and untreated transplanted mice (P = 0.037) by 45% and 43%, respectively (Figure 2A and B) . In addition, corneal APCs of graft recipients treated with Treg cells showed significantly lower levels of MHC class II (as assessed by mean fluorescence intensity) compared to Tconv-treated (P = 0.004) and untreated controls (P = 0.008) ( Figure 2C ). In DLN, the absolute frequencies of CD11b + MHC II + mature APCs were significantly higher in untreated controls (P < 0.0001) and graft recipients treated with Tconv (P = 0.0004) compared with uninflamed corneas of naive nontransplanted mice. However, transplanted mice receiving injection of Treg cells alone, and not Treg cells plus conventional T cells, displayed a significant decrease in the absolute frequencies of mature APCs and APC expression of MHC class II compared to Tconvtreated (P < 0.001 and P < 0.001, respectively) and untreated graft recipients (P = 0.002 and P = 0.002, respectively) ( Figure 2D-F) . 26-28 Therefore, we next assessed the frequencies of IFNγ + CD4 + Th1 cells in the ipsilateral DLNs of allograft recipients 2 weeks after transplantation. Flow cytometry analysis showed significantly higher frequencies of Th1 cells in untreated controls (P = 0.006) and graft recipients treated with Tconv (P = 0.003) compared with naive nontransplanted mice. However, with Treg cell treatment, the frequencies of IFNγ + CD4 + Th1 cells decreased significantly compared with both untreated and Tconv-treated graft recipients (P = 0.048 and P = 0.017, respectively) ( Figures 3A  and B) . Next, we quantified mRNA and protein expression levels of proinflammatory cytokine IFNγ in the ipsilateral cornea at day 14 after transplantation using real-time PCR and ELISA, respectively. Graft recipients treated with Treg cells demonstrated significantly lower IFNγ mRNA levels compared to Tconv-treated controls (P = 0.029) ( Figure  3C ). IFNγ protein levels were undetectable in naïve corneas or Treg cell-treated corneas, but were significantly higher in corneas of Tconv-treated mice (P = 0.003) and untreated controls (P = 0.001) ( Figure 3D ).
Treg Cell Injection Suppresses CD45 + Leukocyte Infiltration Into the Cornea and Increases Expression of Anti-inflammatory Cytokines
To determine whether local injection of Treg cells could suppress ocular inflammation, we examined the frequencies of CD45 + leukocytes infiltrating the grafted corneas using flow cytometry. The frequencies of CD45 + inflammatory cells were significantly decreased in Treg cell-treated graft recipients compared with Tconv-treated and untreated controls (P = 0.016 and P = 0.028, respectively), indicating suppressed corneal inflammation with subconjunctival Treg cell treatment ( Figures 4A and B) . Given that one of the principal mechanisms by which Treg cells suppress effector immune responses is through secretion of IL-10 and TGF-β, 29, 30 we next used ELISA to analyze the protein expression levels of these anti-inflammatory cytokines in ipsilateral corneas of grafted mice at day 14 after transplantation. As shown in Figures 4C and 4D , Treg cell treatment was associated with 4.7-fold and 1.4-fold increase in levels of IL-10 and TGF-β in the ipsilateral cornea of graft recipients compared to untreated controls (P = 0.03 and P = 0.031, respectively). We observed a similar trend in IL-10 and TGF-β levels comparing Treg cell-treated mice with Tconv-treated controls (P = 0.029 and P = 0.057, respectively).
Subconjunctival Injection of Treg Cells Improves Corneal Allograft Survival and Decreases Graft Opacity Scores
Finally, to evaluate the effect of locally delivered Treg cells on long-term allograft survival, graft recipients treated with subconjunctival Treg cells, Tconv or combination of both were examined weekly for graft opacity until week 10 posttransplantation. Transplanted mice not receiving subconjunctival treatment served as controls. Our results revealed significantly lower graft opacity scores in Treg cell-treated group compared with Tconv-treated group and untreated controls (P = 0.017 and P = 0.033 at week 10 after transplantation, respectively) ( Figure 5A ). Allograft recipients who were treated with Treg cells demonstrated significantly higher survival rates (75%) during weeks 3 to 8 after transplantation compared to Tconv-treated (33%, P = 0.033) and untreated control groups (30%, P = 0.029) ( Figure 5B ). These data collectively indicate that Treg cells, but not their effector counterparts, that is, CD4 + CD25 − Tconv or total CD4 + cells (Treg cell+ Tconv), are the cellular component that suppress the effector alloimmune response and improve graft survival.
DISCUSSION
Treg cell-based therapies have been recognized as promising cell-based strategies for induction of tolerance to allografts. 11 The efficacy of Treg cell immunotherapies in restoring immune tolerance has been investigated in several clinical trials for graft-versus-host disease, 31, 32 liver transplantation, 33 type 1 diabetes, 34 and kidney transplantation. 4 The encouraging early results from these trials support further investigations on the role of Treg cells in other organ transplants such as the cornea. Previous studies, including prior investigations from our group, have shown the functional relevance of adoptive transfer of in vitro-expanded Treg cells in promoting corneal allograft survival. [13] [14] [15] In this study we define the mechanism by which local administration of freshly isolated Treg cells alter the host immune response against the allograft. We demonstrate that Treg cells migrate to the cornea and DLNs of grafted mice after subconjunctival injection. Specifically, locally delivered Treg cells inhibit APC maturation, suppress T cell activation, and curb the ocular surface inflammation by upregulating the expression of immunosuppressive cytokines and decreasing leukocyte infiltration to the graft.
Treg cells primarily act in secondary lymphoid tissues to regulate the alloimmune responses. 35 Studies have shown that Treg cells also migrate to the site of graft, where they regulate the ongoing local immune response mediated by alloreactive effector T cells. 36, 37 Herein, we show the dynamics of distribution of Treg cells after subconjunctival injection. Our results demonstrate that locally delivered Treg cells migrate to the ipsilateral DLNs and cornea of grafted mice; they are detected in DLNs of graft recipients as early as 6 hours after injection and reach their maximum frequencies in the cornea after 48 hours. The route of Treg cell administration plays a central role in tissue distribution of Treg cells. It has been reported that after intravenous injection, Treg cells are mainly detected in blood, spleen, and DLN, with only a small number reaching the site of corneal graft. 14, 15 This could explain why previous reports have failed to show any beneficial effects from intravenous injection of natural Treg cells on graft survival. 14, 15 The conjunctiva is highly vascularized and is rich in lymphatic vessels, which allows locally delivered Treg cells to easily home to the DLNs. 38 Subsequent migration of Treg cells to the cornea is dependent on newly formed corneal blood and lymphatic vessels developed after transplantation. 39 Treg cells induce tolerance through different mechanisms, such as direct T cell cytolysis, interleukin-2 deprivation, secretion of inhibitory cytokines IL-10 and IL-35, and APC downregulation. 40 Here we show that locally delivered Treg cells prevent the induction phase of the alloimmune response in DLNs of graft recipients through inhibiting APC maturation and Th1 effector cell activation. We further demonstrate that injected Treg cells regulate the ongoing local immune response at the graft site through upregulating the expression of immunosuppressive cytokines, IL-10 and TGF-β at the ocular surface and by decreasing CD45 + inflammatory cell infiltration into the graft. In a study by Hildebrand et al, the investigators demonstrate that subconjunctival injection of unprimed CD4 We found that the frequencies of injected Treg cells progressively decreased with time, and only a small number of Treg cells could be detected in the conjunctiva by day 7. In regard to the limited life span of Treg cells, 6 ,44 a consideration is if a single injection would be sufficient or whether a second dose of injection is required to further improve graft survival. Guo et al 15 found that adoptive transfer of a second dose of in vitro-activated Treg cells at day 15 after transplantation does not improve graft survival. Cunnusamy et al proposed that Treg cell-mediated suppression is critical for corneal allograft survival during the initial sensitization phase of the alloimmune response, and it is not required after day 30 posttransplantation. 45 The endogenous Treg cells can increase at later time points, serving as a negative feedback loop to prevent excessive damage to the graft. 46 This is consistent with our observation that the immunosuppressive effects of subconjunctivally injected Treg cells last up to day 14 despite the fact that very few Treg cells are detectable on day 7 after transplantation. However, whether a second injection of Treg cells after day 14 will confer additional benefits to graft recipients should be further evaluated.
In summary, our study is the first report to our knowledge to show the dynamics of distribution of Treg cells after subconjunctival injection, and define the mechanism by which locally delivered Treg cells promote allograft survival. Our data demonstrates the efficacy of local delivery of Treg cells in promoting graft survival without requiring prior in vitro − conventional Tcells (Tconv), Treg cell plus Tconv and untreated controls at week 2 posttransplantation. C, The expression levels of IL-10 and TGF-β in cornea after transplantation were evaluated using ELISA. IL-10 and TGF-β levels were significantly higher in Treg cell-treated graft recipients compared to Tconv-treated mice and untreated controls. Data were obtained from n = 6 mice/group and represent mean ± SEM of 2 independent experiments. expansion, which could potentially make the application of Treg-based therapies significantly more feasible in the clinic. These findings have direct implications in transplant immunology and can provide a solid basis for future clinical translational studies using autologous Treg cells to promote allograft survival in human corneal transplantation. − conventional Tcells (Tconv), or Treg cell plus Tconv. Untreated transplanted mice served as the control. Graft survival was monitored for up to 10 weeks posttransplantation. A, Graft opacity scores were significantly lower in Treg cell-treated group compared with Tconv-treated mice and untreated controls. B, Weekly examination of grafts revealed a significant increase in graft survival in Treg cell-treated mice compared with Tconv-treated (75% vs 33%) and untreated controls (75% vs 30%) during weeks 3 to 8 after transplantation. Data are combined from 2 independent experiments (n = 12). Data shown in panel A represent mean ± SEM. Kaplan-Meier curve and Log-rank test were used to determine graft survival in panel B. * P < 0.05 for difference between Treg cell-and Tconv-treated groups, and + P < 0.05 for difference between Treg cell-treated group and untreated transplanted controls.
